Eventide Asset Management, LLC Bluebird Bio, Inc. Transaction History

Eventide Asset Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 21, 2019	SELL	$59.47 - $93.1 $2.14 Million - $3.35 Million	-36,000 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$75.84 - $105.21 $19.6 Million - $27.2 Million	-258,638 Reduced 87.78%	36,000 $4.58 Million
Q1 2019 May 15, 2019	BUY	$64.44 - $104.11 $1.1 Million - $1.77 Million	17,035 Added 6.14%	294,638 $46.4 Million
Q4 2017 Feb 14, 2018	SELL	$81.25 - $130.7 $10.9 Million - $17.6 Million	-134,397 Reduced 32.62%	277,603 $49.4 Million
Q3 2017 Nov 14, 2017	BUY	$57.74 - $91.42 $23.8 Million - $37.7 Million	412,000	412,000 $56.6 Million

42.6M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $466M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Eventide Asset Management, LLC with notifications on news.